These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1276 related articles for article (PubMed ID: 33207094)

  • 41. Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Ma X; Yang S; Zhang K; Xu J; Lv P; Gao H; Qin H; Wang H; Liu X
    Thorac Cancer; 2022 Jun; 13(12):1788-1794. PubMed ID: 35560808
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
    Solomon BJ; Bauer TM; K Mok TS; Liu G; Mazieres J; Marinis F; Goto Y; Kim DW; Wu YL; Jassem J; López FL; Soo RA; Shaw AT; Polli A; Messina R; Iadeluca L; Toffalorio F; Felip E
    Future Oncol; 2023 May; 19(14):961-973. PubMed ID: 37306090
    [TBL] [Abstract][Full Text] [Related]  

  • 43. First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
    Solomon BJ; Mok T; Kim DW; Wu YL; Nakagawa K; Mekhail T; Felip E; Cappuzzo F; Paolini J; Usari T; Iyer S; Reisman A; Wilner KD; Tursi J; Blackhall F;
    N Engl J Med; 2014 Dec; 371(23):2167-77. PubMed ID: 25470694
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Canadian perspectives: update on inhibition of
    Melosky B; Cheema P; Agulnik J; Albadine R; Bebb DG; Blais N; Burkes R; Butts C; Card PB; Chan AMY; Hirsh V; Ionescu DN; Juergens R; Morzycki W; Poonja Z; Sangha R; Tehfe M; Tsao MS; Vincent M; Xu Z; Liu G
    Curr Oncol; 2018 Oct; 25(5):317-328. PubMed ID: 30464681
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer.
    Solomon BJ; Bauer TM; de Marinis F; Felip E; Goto Y; Liu G; Mazieres J; Kim DW; Mok T; Polli A; Thurm H; Calella AM; Peltz G; Shaw AT
    Future Oncol; 2021 Dec; 17(34):4649-4656. PubMed ID: 34585621
    [TBL] [Abstract][Full Text] [Related]  

  • 46. First-Line Lorlatinib Versus Crizotinib in
    Hayashi H; Teraoka S; Goto Y; Kumagai T; Nishio M; Sugawara S; Oizumi S; Matsumura M; Okura M; Peltz G; Kato T
    JTO Clin Res Rep; 2023 Apr; 4(4):100471. PubMed ID: 37007870
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
    Horn L; Wang Z; Wu G; Poddubskaya E; Mok T; Reck M; Wakelee H; Chiappori AA; Lee DH; Breder V; Orlov S; Cicin I; Cheng Y; Liu Y; Fan Y; Whisenant JG; Zhou Y; Oertel V; Harrow K; Liang C; Mao L; Selvaggi G; Wu YL
    JAMA Oncol; 2021 Nov; 7(11):1617-1625. PubMed ID: 34473194
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
    Yanagitani N; Uchibori K; Koike S; Tsukahara M; Kitazono S; Yoshizawa T; Horiike A; Ohyanagi F; Tambo Y; Nishikawa S; Fujita N; Katayama R; Nishio M
    Cancer Sci; 2020 Mar; 111(3):932-939. PubMed ID: 31961053
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC.
    Arnaoutakis K; Wan Y; Elliott J; Young M; Yin Y; Leventakos K; Lin HM; Dimou A
    Adv Ther; 2024 Aug; 41(8):3217-3231. PubMed ID: 38916812
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece.
    Gourzoulidis G; Zisimopoulou O; Liavas A; Tzanetakos C
    Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):375-385. PubMed ID: 37997764
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
    Zhou C; Kim SW; Reungwetwattana T; Zhou J; Zhang Y; He J; Yang JJ; Cheng Y; Lee SH; Bu L; Xu T; Yang L; Wang C; Liu T; Morcos PN; Lu Y; Zhang L
    Lancet Respir Med; 2019 May; 7(5):437-446. PubMed ID: 30981696
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
    Popat S; Liu G; Lu S; Song G; Ma X; Yang JC
    Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
    Ma HC; Liu YH; Ding KL; Liu YF; Zhao WJ; Zhu YJ; Chang XS; Chen YD; Xiao ZZ; Yu YY; Zhou R; Zhang HB
    BMC Cancer; 2021 Nov; 21(1):1278. PubMed ID: 34836510
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
    Shaw AT; Kim DW; Nakagawa K; Seto T; Crinó L; Ahn MJ; De Pas T; Besse B; Solomon BJ; Blackhall F; Wu YL; Thomas M; O'Byrne KJ; Moro-Sibilot D; Camidge DR; Mok T; Hirsh V; Riely GJ; Iyer S; Tassell V; Polli A; Wilner KD; Jänne PA
    N Engl J Med; 2013 Jun; 368(25):2385-94. PubMed ID: 23724913
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
    BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
    [TBL] [Abstract][Full Text] [Related]  

  • 56. From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC.
    Ou SI; Lee ATM; Nagasaka M
    Crit Rev Oncol Hematol; 2023 Jul; 187():104019. PubMed ID: 37187318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.
    Ou SI; Solomon BJ; Shaw AT; Gadgeel SM; Besse B; Soo RA; Abbattista A; Toffalorio F; Wiltshire R; Bearz A
    J Thorac Oncol; 2022 Apr; 17(4):568-577. PubMed ID: 35026476
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
    Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
    Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An update on lorlatinib: a novel first line treatment for
    Riudavets M; Planchard D
    Expert Opin Pharmacother; 2023 Feb; 24(3):291-299. PubMed ID: 36542835
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic.
    Miloš P; Jana S; Vítězslav K; Monika Š; Leona K; Jaromír R; Renata C; Markéta Č; Andrea B; Juraj K; Michal H; Milada Z; Marek K; Helena Č; Martin S
    Klin Onkol; 2018; 31(3):207-212. PubMed ID: 30441974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 64.